Protease inhibitors: a tale of two companies
Article Abstract:
Merck and Abbott developed the protease inhibitors ritonavir and indinavir that when used with other anti-HIV drugs can reduce the amount of HIV in most infected people to levels that are not even detectable. The companies' different corporate, scientific and political strategies are examined.
Publication Name: Science
Subject: Science and technology
ISSN: 0036-8075
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Exclusive license rankles genome researchers
Article Abstract:
Stanford University made a controversial decision to sell an exclusive license to a machine that makes oligonucleotides to Protogene, which refuses to sell the machine. Researchers maintain the exclusive agreement is hampering genetic research.
Publication Name: Science
Subject: Science and technology
ISSN: 0036-8075
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Glossy strategic plan hits the streets. Center for the mind pleases the senses. Childhood vaccines: the R&D factor
- Abstracts: Atrazine found to cause chromosonal breaks. New method measures exposure to volatile organics. Recycling not profitable
- Abstracts: Maintaining a Nuclear Deterrent Under the Test Ban Treaty. Minerals in the deep Earth: a message from the asteroid belt
- Abstracts: Stochastic aspects of matrix cracking in brittle matrix composites. Finite element simulations of fiber pull-out
- Abstracts: Applicability of Neuber's rule to the analysis of stress and strain concentration under creep conditions. Compressive failure of fiber composites: the roles of multiaxial loading and creep